Antiangiogenic therapy: impact on invasion, disease progression, and metastasis (original) (raw)

• US Department of Health and Human Services FDA US Food and Drug Administration [online], (2011).
• Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186 (1971).
  CAS PubMed Google Scholar
• Abdollahi, A. & Folkman, J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist. Updat. 13, 16–28 (2010).
  CAS PubMed Google Scholar
• Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592–603 (2008).
  CAS PubMed PubMed Central Google Scholar
• Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232–239 (2009).
  CAS PubMed PubMed Central Google Scholar
• Pàez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220–231 (2009).
  PubMed PubMed Central Google Scholar
• Allegra, C. J. et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J. Clin. Oncol. 29, 11–16 (2011).
  CAS PubMed Google Scholar
• de Gramont, A. et al. AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer [abstract]. J. Clin. Oncol. 29 (Suppl. 4), a362 (2011).
  Google Scholar
• Miles, D. et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J. Clin. Oncol. 29, 83–88 (2011).
  Article CAS PubMed Google Scholar
• Bagri, A., Kouros-Mehr, H., Leong, K. G. & Plowman, G. D. Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale. Trends Mol. Med. 16, 122–132 (2010).
  CAS PubMed Google Scholar
• Heath, V. L. & Bicknell, R. Anticancer strategies involving the vasculature. Nat. Rev. Clin. Oncol. 6, 395–404 (2009).
  CAS PubMed Google Scholar
• Boere, I. A., Hamberg, P. & Sleijfer, S. It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies. Cancer Sci. 101, 7–15 (2010).
  CAS PubMed Google Scholar
• Ivy, S. P., Wick, J. Y. & Kaufman, B. M. An overview of small-molecule inhibitors of VEGFR signaling. Nat. Rev. Clin. Oncol. 6, 569–579 (2009).
  CAS PubMed Google Scholar
• Kerbel, R. S. Tumor angiogenesis. N. Engl. J. Med. 358, 2039–2049 (2008).
  CAS PubMed PubMed Central Google Scholar
• Saltz, L. B. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 26, 2013–2019 (2008).
  CAS PubMed Google Scholar
• Wilkerson, J. & Fojo, T. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival. Cancer J. 15, 379–385 (2009).
  PubMed Google Scholar
• Wolter, P., Beuselinck, B., Pans, S. & Schöffski, P. Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors. Acta Oncol. 48, 621–624 (2009).
  CAS PubMed Google Scholar
• Desar, I. M. et al. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. Acta Oncol. 48, 927–931 (2009).
  PubMed Google Scholar
• Cacheux, W. et al. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann. Oncol. 19, 1659–1661 (2008).
  CAS PubMed Google Scholar
• Stein, W. D., Yang, J., Bates, S. E. & Fojo, T. Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist 13, 1055–1062 (2008).
  CAS PubMed Google Scholar
• Mancuso, M. R. et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116, 2610–2621 (2006).
  CAS PubMed PubMed Central Google Scholar
• Levashova, Z. et al. Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors. J. Nucl. Med. 51, 959–966 (2010).
  CAS PubMed Google Scholar
• Nagengast, W. B. et al. VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res. 71, 143–153 (2011).
  CAS PubMed Google Scholar
• di Tomaso, E. et al. Glioblastoma recurrence after cediranib therapy in patients: lack of “rebound” revascularization as mode of escape. Cancer Res. 71, 19–28 (2011).
  CAS PubMed PubMed Central Google Scholar
• La Vine, D. B., Coleman, T. A., Davis, C. H., Carbonell, C. E. & Davis, W. B. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. Am. J. Clin. Oncol. 33, 217–220 (2010).
  CAS PubMed Google Scholar
• Gore, M. E. et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 10, 757–763 (2009).
  CAS PubMed Google Scholar
• van der Veldt, A. A. et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br. J. Cancer 99, 259–265 (2008).
  CAS PubMed PubMed Central Google Scholar
• Riechelmann, R. P. et al. Sorafenib for metastatic renal cancer: the Princess Margaret experience. Am. J. Clin. Oncol. 31, 182–187 (2008).
  CAS PubMed Google Scholar
• Yoo, C. et al. The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn. J. Clin. Oncol. 40, 980–985 (2010).
  PubMed Google Scholar
• Johannsen, M. et al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur. Urol. 55, 1430–1438 (2009).
  CAS PubMed Google Scholar
• Sablin, M. P. et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J. Urol. 182, 29–34 (2009).
  CAS PubMed Google Scholar
• Dudek, A. Z., Zolnierek, J., Dham, A., Lindgren, B. R. & Szczylik, C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115, 61–67 (2009).
  CAS PubMed Google Scholar
• Tamaskar, I. et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J. Urol. 179, 81–86 (2008).
  CAS PubMed Google Scholar
• Hammers, H. J. et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol. Cancer Ther. 9, 1525–1535 (2010).
  CAS PubMed PubMed Central Google Scholar
• Ellis, L. M. & Haller, D. G. Bevacizumab beyond progression: does this make sense? J. Clin. Oncol. 26, 5313–5315 (2008).
  PubMed Google Scholar
• Cohn, A. L. et al. Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP) [abstract]. J. Clin. Oncol. 28 (Suppl.), a3596 (2010).
  Google Scholar
• Burger, R. A. et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study [abstract]. J. Clin. Oncol. 28 (Suppl.), aLBA1 (2010).
  Google Scholar
• Perren, T. et al. ICON7: A phase III Gynaecologic Cancer InterGroup (GCIG) trial of adding bevacizumab to standard chemotherapy in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer [abstract]. Ann. Oncol. 21 (Suppl. 8), aLBA3 (2010).
  Google Scholar
• Ebos, J. M., Lee, C. R. & Kerbel, R. S. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin. Cancer Res. 15, 5020–5025 (2009).
  CAS PubMed PubMed Central Google Scholar
• Norden, A. D. et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70, 779–787 (2008).
  CAS PubMed Google Scholar
• Narayana, A. et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J. Neurosurg. 110, 173–180 (2009).
  PubMed Google Scholar
• Fischer, I. et al. High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neuro. Oncol. 10, 700–708 (2008).
  PubMed PubMed Central Google Scholar
• Ellis, L. M. & Reardon, D. A. Cancer: The nuances of therapy. Nature 458, 290–292 (2009).
  CAS PubMed Google Scholar
• Mathews, M. S., Linskey, M. E., Hasso, A. N. & Fruehauf, J. P. The effect of bevacizumab (Avastin) on neuroimaging of brain metastases. Surg. Neurol. 70, 649–652 (2008).
  PubMed Google Scholar
• Zuniga, R. M. et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J. Neurooncol. 91, 329–336 (2009).
  CAS PubMed Google Scholar
• Iwamoto, F. M. et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73, 1200–1206 (2009).
  CAS PubMed PubMed Central Google Scholar
• Zuniga, R. M. et al. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J. Neurooncol. 99, 237–242 (2010).
  CAS PubMed Google Scholar
• Verhoeff, J. J. et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 9, 444 (2009).
  PubMed PubMed Central Google Scholar
• Narayana, A. et al. Bevacizumab in recurrent high-grade pediatric gliomas. Neuro. Oncol. 12, 985–990 (2010).
  CAS PubMed PubMed Central Google Scholar
• Narayana, A. et al. Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. Int. J. Radiat. Oncol. Biol. Phys. doi: 10.1016/j.ijrobp.2010.10.038.
  PubMed Google Scholar
• Rubenstein, J. L. et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2, 306–314 (2000).
  CAS PubMed PubMed Central Google Scholar
• Kunkel, P. et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 61, 6624–6628 (2001).
  CAS PubMed Google Scholar
• Blouw, B. et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4, 133–146 (2003).
  CAS PubMed Google Scholar
• Verhoeff, J. J. et al. Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma. Eur. J. Cancer 45, 3074–3080 (2009).
  CAS PubMed Google Scholar
• Lucio-Eterovic, A. K., Piao, Y. & de Groot, J. F. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin. Cancer Res. 15, 4589–4599 (2009).
  CAS PubMed Google Scholar
• Gomez-Manzano, C. et al. VEGF Trap induces antiglioma effect at different stages of disease. Neuro. Oncol. 10, 940–945 (2008).
  PubMed PubMed Central Google Scholar
• de Groot, J. F. et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro. Oncol. 12, 233–242 (2010).
  CAS PubMed PubMed Central Google Scholar
• Lamszus, K. et al. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin. Cancer Res. 11, 4934–4940 (2005).
  CAS PubMed Google Scholar
• Leenders, W. P. et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin. Cancer Res. 10, 6222–6230 (2004).
  CAS PubMed Google Scholar
• Chamberlain, M. C. Radiographic patterns of relapse in glioblastoma. J. Neurooncol. 101, 319–323 (2011).
  PubMed Google Scholar
• Petrelli, F., Cabiddu, M., Carpo, M., Ghilardi, M. & Barni, S. Progression of intramedullary metastasis during perioperative cessation of sunitinib. Nat. Rev. Urol. 7, 634–637 (2010).
  CAS PubMed Google Scholar
• Plimack, E. R., Tannir, N., Lin, E., Bekele, B. N. & Jonasch, E. Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer 115, 1859–1866 (2009).
  CAS PubMed Google Scholar
• Crawford, Y. & Ferrara, N. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol. Sci. 30, 624–630 (2009).
  CAS PubMed Google Scholar
• Nguyen, D. X., Bos, P. D. & Massagué, J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 9, 274–284 (2009).
  CAS PubMed Google Scholar
• Paget, S. The distribution of secondary growths in cancer of the breast. Lancet 133, 571–573 (1889).
  Google Scholar
• Hirota, K. & Semenza, G. L. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit. Rev. Oncol. Hematol. 59, 15–26 (2006).
  PubMed Google Scholar
• Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J. & Kerbel, R. S. Effect of p53 status on tumor response to antiangiogenic therapy. Science 295, 1526–1528 (2002).
  CAS PubMed Google Scholar
• Rapisarda, A. & Melillo, G. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist. Updat. 12, 74–80 (2009).
  CAS PubMed PubMed Central Google Scholar
• Pennacchietti, S. et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347–361 (2003).
  PubMed Google Scholar
• Steeg, P. S. Angiogenesis inhibitors: motivators of metastasis? Nat. Med. 9, 822–823 (2003).
  CAS PubMed Google Scholar
• Blagosklonny, M. V. Antiangiogenic therapy and tumor progression. Cancer Cell 5, 13–17 (2004).
  CAS PubMed Google Scholar
• Bidard, F. C., Pierga, J. Y., Vincent-Salomon, A. & Poupon, M. F. A “class action” against the microenvironment: do cancer cells cooperate in metastasis? Cancer Metastasis Rev. 27, 5–10 (2008).
  CAS PubMed PubMed Central Google Scholar
• Solinas, G., Marchesi, F., Garlanda, C., Mantovani, A. & Allavena, P. Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev. 29, 243–248 (2010).
  CAS PubMed Google Scholar
• Xian, X. et al. Pericytes limit tumor cell metastasis. J. Clin. Invest. 116, 642–651 (2006).
  CAS PubMed PubMed Central Google Scholar
• Francia, G., Cruz-Munoz, W., Man, S., Xu, P. & Kerbel, R. S. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat. Rev. Cancer 11, 135–141 (2011).
  CAS PubMed PubMed Central Google Scholar
• Bos, P. D., Nguyen, D. X. & Massagué, J. Modeling metastasis in the mouse. Curr. Opin. Pharmacol. 10, 571–577 (2010).
  CAS PubMed PubMed Central Google Scholar
• Hu-Lowe, D. D. et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin. Cancer Res. 14, 7272–7283 (2008).
  CAS PubMed Google Scholar
• Schomber, T. et al. Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis. Mol. Cancer Ther. 8, 55–63 (2009).
  CAS PubMed Google Scholar
• Yin, J. J., Zhang, L., Munasinghe, J., Linnoila, R. I. & Kelly, K. Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer. Cancer Res. 70, 8662–8673 (2010).
  CAS PubMed Google Scholar
• Steeg, P. S. & Theodorescu, D. Metastasis: a therapeutic target for cancer. Nat. Clin. Pract. Oncol. 5, 206–219 (2008).
  CAS PubMed PubMed Central Google Scholar
• Padera, T. P. et al. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol. Cancer Ther. 7, 2272–2279 (2008).
  CAS PubMed PubMed Central Google Scholar
• Lee, Y. J. et al. Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment. Cancer Res. 70, 8357–8367 (2010).
  CAS PubMed PubMed Central Google Scholar
• Gandhi, L. et al. Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis. Cancer Prev. Res. (Phila) 2, 330–337 (2009).
  CAS Google Scholar
• Grandis, J. R. & Argiris, A. Targeting angiogenesis from premalignancy to metastases. Cancer Prev. Res. (Phila) 2, 291–294 (2009).
  CAS Google Scholar
• Singh, M. et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat. Biotechnol. 28, 585–593 (2010).
  CAS PubMed Google Scholar
• Bose, D. et al. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 11, 373–382 (2010).
  CAS PubMed Google Scholar
• US National Institutes of Health Clinical Trials [online], (2011).
• Allegra, C. J. et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J. Clin. Oncol. 27, 3385–3390 (2009).
  CAS PubMed PubMed Central Google Scholar
• Wolmark, N. et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08 [abstract]. J. Clin. Oncol. 27 (Suppl.), aLBA4 (2009).
  Google Scholar
• Kinoshita, T. et al. Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: a case report. Int. J. Urol. 17, 286–288 (2010).
  PubMed Google Scholar
• Altorki, N. et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J. Clin. Oncol. 28, 3131–3137 (2010).
  CAS PubMed Google Scholar
• Dawson, M. R., Duda, D. G., Chae, S. S., Fukumura, D. & Jain, R. K. VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation. PLoS ONE 4, e6525 (2009).
  PubMed PubMed Central Google Scholar
• Steeg, P. S. et al. Preclinical drug development must consider the impact on metastasis. Clin. Cancer Res. 15, 4529–4530 (2009).
  PubMed PubMed Central Google Scholar
• Mack, G. S. & Marshall, A. Lost in migration. Nat. Biotechnol. 28, 214–229 (2010).
  CAS PubMed Google Scholar
• Francia, G. & Kerbel, R. S. Raising the bar for cancer therapy models. Nat. Biotechnol. 28, 561–562 (2010).
  CAS PubMed Google Scholar
• Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).
  CAS PubMed Google Scholar
• Giantonio, B. J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25, 1539–1544 (2007).
  CAS PubMed Google Scholar
• Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666–2676 (2007).
  CAS PubMed Google Scholar
• Miles, D. W. et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28, 3239–3247 (2010).
  CAS PubMed Google Scholar
• Robert, N. J. et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) [abstract]. J. Clin. Oncol. 27 (Suppl.), a1005 (2009).
  Google Scholar
• Brufsky, A. et al. Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC) [abstract]. J. Clin. Oncol. 28 (Suppl.), a1021 (2010).
  Google Scholar
• Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542–2550 (2006).
  CAS PubMed Google Scholar
• Reck, M. et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann. Oncol. 21, 1804–1809 (2010).
  CAS PubMed PubMed Central Google Scholar
• Kabbinavar, F. F., Miller, V. A., Johnson, B. E., O'Connor, P. G. & Soh, C. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 28 (Suppl.), a7526 (2010).
  Google Scholar
• Escudier, B. et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 28, 2144–2150 (2010).
  CAS PubMed Google Scholar
• Rini, B. I. et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 28, 2137–2143 (2010).
  CAS PubMed PubMed Central Google Scholar
• Cohen, M. H., Shen, Y. L., Keegan, P. & Pazdur, R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14, 1131–1138 (2009).
  CAS PubMed Google Scholar
• Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584–3590 (2009).
  CAS PubMed PubMed Central Google Scholar
• Goodman, V. L. et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res. 13, 1367–1373 (2007).
  CAS PubMed Google Scholar
• Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501–513 (2011).
  CAS PubMed Google Scholar
• Escudier, B. et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27, 3312–3218 (2009).
  CAS PubMed Google Scholar
• Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
  CAS PubMed Google Scholar
• Sternberg, C. N. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28, 1061–1068 (2010).
  CAS PubMed Google Scholar
• Herbst, R. S. et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 11, 619–626 (2010).
  CAS PubMed PubMed Central Google Scholar
• Hecht, J. R. et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27, 672–680 (2009).
  CAS PubMed Google Scholar
• Tol, J. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563–572 (2009).
  CAS PubMed Google Scholar
• Miller, K. D. et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23, 792–799 (2005).
  CAS PubMed Google Scholar
• Jones, D. Avastin-Tarceva combination fails in lung cancer. Nat. Biotechnol. 27, 108–109 (2009).
  CAS PubMed Google Scholar
• Kang, Y. et al. AVAGAST: A randomized double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC) [abstract]. J. Clin. Oncol. 28 (Suppl.), aLBA4007 (2010).
  Google Scholar
• Kindler, H. L. et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28, 3617–3622 (2010).
  CAS PubMed PubMed Central Google Scholar
• Van Cutsem, E. et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 27, 2231–2237 (2009).
  CAS PubMed Google Scholar
• Kelly, W. K. et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxol, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALB 90401 [abstract]. J. Clin. Oncol. 28 (Suppl.), aLBA4511 (2010).
  Google Scholar
• Crown, J. et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC) [abstract]. J. Clin. Oncol. 28 (Suppl.), aLBA1011 (2010).
  Google Scholar
• Barrios, C. H. et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res. Treat. 121, 121–131 (2010).
  CAS PubMed PubMed Central Google Scholar
• Scagliotti, G. et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 1835–1842 (2010).
  CAS PubMed Google Scholar
• Kohne, C. et al. Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo [abstract]. J. Clin. Oncol. 25 (Suppl.), a4033 (2007).
  Google Scholar
• Natale, R. B. et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. doi: 10.1200/JCO.2010.28.5981
  CAS PubMed Google Scholar
• de Boer, R. H. et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. doi: 10.1200/JCO.2010.29.5717
  CAS PubMed Google Scholar
• Batchelor, T. T. et al. A phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recuttrent glioblastoma patients [abstract]. Ann. Oncol. 21 (Suppl. 8), aLBA7 (2010).
  Google Scholar
• von Essen, C. F. Radiation enhancement of metastasis: a review. Clin. Exp. Metastasis 9, 77–104 (1991).
  CAS PubMed Google Scholar
• Kargiotis, O., Geka, A., Rao, J. S. & Kyritsis, A. P. Effects of irradiation on tumor cell survival, invasion and angiogenesis. J. Neurooncol. 100, 323–338 (2010).
  PubMed Google Scholar
• Bagri, A. et al. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin. Cancer Res. 16, 3887–3900 (2010).
  CAS PubMed Google Scholar
• Kienast, Y. et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat. Med. 16, 116–122 (2010).
  CAS PubMed Google Scholar
• Lee, S. L. et al. Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc. Natl Acad. Sci. USA 106, 19485–19490 (2009).
  CAS PubMed PubMed Central Google Scholar
• Ellis, L. M. & Reardon, D. A. Is there really a yin and yang to VEGF-targeted therapies? Lancet Oncol. 11, 809–811 (2010).
  PubMed Google Scholar
• Van Cutsem, E., Lambrechts, D., Prenen, H., Jain, R. K. & Carmeliet, P. Lessons from the adjuvant bevacizumab trial on colon cancer: what next? J. Clin. Oncol. 29, 1–4 (2011).
  CAS PubMed Google Scholar
• Saidi, A. et al. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Int. J. Cancer 125, 1054–1064 (2009).
  CAS PubMed Google Scholar
• Rofstad, E. K. & Halsør, E. F. Hypoxia-associated spontaneous pulmonary metastasis in human melanoma xenografts: involvement of microvascular hot spots induced in hypoxic foci by interleukin 8. Br. J. Cancer 86, 301–308 (2002).
  CAS PubMed PubMed Central Google Scholar
• Rofstad, E. K. et al. Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res. 62, 1847–1853 (2002).
  CAS PubMed Google Scholar
• Galluzzo, M., Pennacchietti, S., Rosano, S., Comoglio, P. M. & Michieli, P. Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis. J. Clin. Invest. 119, 865–875 (2009).
  CAS PubMed PubMed Central Google Scholar
• Cairns, R. A., Khokha, R. & Hill, R. P. Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr. Mol. Med. 3, 659–671 (2003).
  CAS PubMed Google Scholar
• Park, J. E. et al. Hypoxia tumor cell modulates its microenvironment to enhance angiogenic and metastastic potential by secretion of proteins and exosomes. Mol. Cell. Proteomics 9, 1085–1099 (2010).
  CAS PubMed PubMed Central Google Scholar
• Du, R. et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13, 206–220 (2008).
  CAS PubMed PubMed Central Google Scholar
• Cairns, R. A. & Hill, R. P. Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res. 64, 2054–2061 (2004).
  CAS PubMed Google Scholar
• Cairns, R. A., Kalliomaki, T. & Hill, R. P. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res. 61, 8903–8908 (2001).
  CAS PubMed Google Scholar
• Rofstad, E. K., Gaustad, J. V., Egeland, T. A., Mathiesen, B. & Galappathi, K. Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination. Int. J. Cancer 127, 1535–1546 (2010).
  CAS PubMed Google Scholar
• Higgins, D. F. et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J. Clin. Invest. 117, 3810–3820 (2007).
  CAS PubMed PubMed Central Google Scholar
• Casanovas, O., Hicklin, D. J., Bergers, G. & Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299–309 (2005).
  CAS PubMed Google Scholar
• Martinez-Outschoorn, U. E. et al. The autophagic tumor stroma model of cancer or “battery-operated tumor growth”: A simple solution to the autophagy paradox. Cell Cycle 9, 4297–4306 (2010).
  CAS PubMed PubMed Central Google Scholar
• Ricci-Vitiani, L. et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468, 824–828 (2010).
  CAS PubMed Google Scholar
• Wang, R. et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468, 829–833 (2010).
  CAS PubMed Google Scholar
• Crawford, Y. et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15, 21–34 (2009).
  CAS PubMed Google Scholar
• Ebos, J. M., Lee, C. R., Christensen, J. G., Mutsaers, A. J. & Kerbel, R. S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc. Natl Acad. Sci. USA 104, 17069–17074 (2007).
  CAS PubMed PubMed Central Google Scholar
• Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83–95 (2007).
  CAS PubMed PubMed Central Google Scholar
• Lewis, C. E., De Palma, M. & Naldini, L. Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res. 67, 8429–8432 (2007).
  CAS PubMed Google Scholar
• Shojaei, F. et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 25, 911–920 (2007).
  CAS PubMed Google Scholar
• Joyce, J. A. & Pollard, J. W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9, 239–252 (2009).
  CAS PubMed Google Scholar
• Shojaei, F. et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl Acad. Sci. USA 106, 6742–6747 (2009).
  CAS PubMed PubMed Central Google Scholar
• Kaplan, R. N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820–827 (2005).
  CAS PubMed PubMed Central Google Scholar
• Steeg, P. S. Cancer biology: emissaries set up new sites. Nature 438, 750–751 (2005).
  CAS PubMed Google Scholar
• Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. & Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287–1295 (2003).
  CAS PubMed PubMed Central Google Scholar
• Hirschi, K. K. & D'Amore, P. A. Control of angiogenesis by the pericyte: molecular mechanisms and significance. EXS 79, 419–428 (1997).
  CAS PubMed Google Scholar
• Elice, F., Rodeghiero, F., Falanga, A. & Rickles, F. R. Thrombosis associated with angiogenesis inhibitors. Best. Pract. Res. Clin. Haematol. 22, 115–128 (2009).
  CAS PubMed Google Scholar
• Reynolds, A. R. et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat. Med. 15, 392–400 (2009).
  CAS PubMed Google Scholar